News
News affecting the practice of veterinary medicine and the care of animals.
News affecting the practice of veterinary medicine and the care of animals.
Merck Animal Health is recalling three batches of BANAMINE®/BANAMINE®-S 50 mg/mL due to the presence of particulate matter.
Show your support for the OSU CCVM Class of 2027 by donating a white coat and stethoscope.
To renew your OVMA membership, please login to your member account. On your account page, you will see a link to renew your membership.
Inmar Supply Chain Solutions, LLC is voluntarily recalling some FDA regulated products, which may have included animal drugs, due to heat and possible contact with rodents.
The Oregon Board of Pharmacy decided to not adopt its proposed rule to designate xylazine as a Schedule I drug.
Ozona Organics Dog, Cat, Equine, and Swine Probiotics are being recalled in their entirety. The distribution dates for affected product are from August 2021 through July 2023.
The Oregon State University Carlson College of Veterinary Medicine Disaster Action Management Team provides disaster response training and education to veterinary professionals and students.
If you have concerns about the proposed rule on xylazine, the OVMA encourages you to submit public comments by July 26, 2023 at 4:30 pm to: pharmacy.rulemaking@bop.oregon.gov.
If you have concerns about the proposed rule on compounding, the OVMA encourages you to submit public comments by July 26, 2023 at 4:30 pm to: pharmacy.rulemaking@bop.oregon.gov.
Getting nipped at by anxious canine patients is a potential hazard of the job for veterinary team members, and knowing what to do in the wake of a dog bite is crucial.
The combination medicated feed containing Safe-Guard (fenbendazole) and Lincomix (lincomycin), under the New Animal Drug Application (NADA) 140-954, for use in swine, has been withdrawn from the market.
Updates on the OVMA's advocacy efforts in the 2023 Oregon Legislature on behalf of the veterinary profession.
Savannah Bowles and Brooklen Walker, both OSU CCVM students, were recipients of this year's OVMA/AHFO scholarships.
The Oregon Board of Pharmacy (OBOP) is expected to amend OAR 855-080-0021 by adding “Xylazine, unless in the form of an FDA-approved product” to Schedule I.
A work group, assigned by the Oregon Board of Pharmacy (OBOP) to address compounding in human and veterinary medicine, has developed an initial draft of regulations that will be taken into consideration by the agency’s board of directors.
The Akorn Trustee is initiating a voluntary recall of various within-expiry human and animal products as a result of the closures and discontinuation of the quality activities of these marketed products.